11.09.2014 • News

Almac Joins Academic and Industrial Partners to Find Green Chemicals

Almac, the contract development and manufacturing organization based at Craigavon, UK, has announced its "high level" participation in a synthetic biology project to develop novel routes to chemicals. Other academic and industrial partners include Bangor University of Wales and Hockley International, a Manchester, England-based manufacturer and exporter of environmental health and industrial chemical products.

The research team has received a grant of £1 million from the UK's Biotechnology & Biological Sciences Research Council and Technology Strategy Board. The funding is specifically targeted at bringing a novel chemical produced via an enzymatic route from under-utilized natural oil to the market.

Almac is currently performing the R&D work at its Northern Ireland-based laboratories, partnering with experts from both the university's College of Natural Sciences and Hockley to steer the project over a three year period.

The company said its head of biocatalysis & isotope chemistry, Professor Tom Moody, has cultivated considerable enzyme technology experience and expertise over the past decade, and collaboration in this research is especially important for the development of green processes in this industry.

The work will involve close collaboration between Almac, Hockley and the biocomposites center at Bangor University's School of Biological Sciences.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read